Its interactions with binding proteins—such as CD44, EGFR, integrins, CD280, and CD176—and its dual role in both tumor and stromal compartments highlight a unique therapeutic vulnerability that extends beyond conventional single-pathway targeting strategies. The gene discussed is MRC2; the disease is neoplasm.